Correction: Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Prolonged Survival Observed with Boron Neutron Capture Therapy in a Rat Model of Multifocal Brain Metastases

  • By

  • Rina Shidoh-Kazuki

  • Yoshiki Fujikawa

  • Shinji Kawabata

  • Kohei Tsujino

  • Hironori Yamada

  • Fugen Takagi

  • Hideki Kashiwagi

  • Ryo Hiramatsu

  • Naosuke Nonoguchi

  • Toshihiro Takami

  • Naonori Hu

  • Takushi Takata

  • Hiroki Tanaka

  • Minoru Suzuki

  • Masahiko Wanibuchi

  • June 4, 2026

Share

Correction: Prolonged Survival Observed with Boron Neutron Capture Therapy

Overview

This report corrects an error in the formula presented in the original article regarding Boron Neutron Capture Therapy (BNCT) in a rat model of multifocal brain metastases. The correction clarifies the experimental design and treatment groups.

Background

Boron Neutron Capture Therapy (BNCT) is an investigational treatment modality for brain metastases. The accurate representation of experimental designs is crucial for the interpretation of clinical outcomes.

Data Highlights

No numerical or trial data presented in the correction article.

Key Findings

  • The original article contained a formula error that has been corrected.
  • BNCT is investigational for brain metastases.
  • Preclinical studies suggest BNCT can spare immune cells while inducing anti-tumor immunity.
  • BNCT received clinical approval in Japan for unresectable, locally recurrent head and neck cancer.
  • Recent studies have reported partial responses in patients with recurrent breast cancer treated with BNCT.

Clinical Implications

The correction of the formula in the experimental design is essential for accurate interpretation of BNCT's efficacy in treating brain metastases.

Conclusion

This correction emphasizes the importance of precision in scientific reporting, particularly in experimental therapies like BNCT for brain metastases.

Related Resources & Content

  1. Journal of Neuro-Oncology, 2026 -- Correction: Prolonged Survival Observed with Boron Neutron Capture Therapy in a Rat Model of Multifocal Brain Metastases
  2. Journal of Neuro-Oncology — Boron Neutron Capture Therapy for Recurrent Meningiomas: An Evaluation of Dosimetric Parameters and Clinical Outcomes
  3. Journal of Neuro-Oncology — Evolving Survival Outcomes in Non-Small Cell Lung Cancer Patients with and without Brain Metastases Undergoing Advanced Treatment Approaches
  4. The ASCO Post — Expert Point of View: Andrew B. ­Lassman, MD
  5. Journal of Neuro-Oncology — Impact of Integrating Targeted Therapies or Chemotherapy with Stereotactic Radiosurgery (SRS) on Outcomes for Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)
  6. Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial - PubMed
  7. Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model | Nature Communications

Original Source(s)

Correction: Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases

  • by Rina Shidoh-Kazuki, Yoshiki Fujikawa, Shinji Kawabata, Kohei Tsujino, Hironori Yamada, Fugen Takagi, Hideki Kashiwagi, Ryo Hiramatsu, Naosuke Nonoguchi, Toshihiro Takami, Naonori Hu, Takushi Takata, Hiroki Tanaka, Minoru Suzuki, Masahiko Wanibuchi

  • June 4, 2026

Related Content

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min
Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min